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Abstract Membrane transporters play an essential role in
the transport of endogenous and exogenous compounds,
and consequently they mediate the uptake, distribution, and
excretion of many drugs. The clinical relevance of trans-
porters in drug disposition and their effect in adults have
been shown in drug–drug interaction and pharmacoge-
nomic studies. Little is known, however, about the onto-
geny of human membrane transporters and their roles in
pediatric pharmacotherapy. As they are involved in the
transport of endogenous substrates, growth and develop-
ment may be important determinants of their expression
and activity. This review presents an overview of our
current knowledge on human membrane transporters in
pediatric drug disposition and effect. Existing pharma-
cokinetic and pharmacogenetic data on membrane sub-
strate drugs frequently used in children are presented and
related, where possible, to existing ex vivo data, providing
a basis for developmental patterns for individual human
membrane transporters. As data for individual transporters
are currently still scarce, there is a striking information gap
regarding the role of human membrane transporters in drug
therapy in children.
Key Points
Little is known about the ontogeny of transporters
and their roles in pediatric pharmacotherapy.
Ex vivo, pharmacokinetic and pharmacogenetic
studies suggest transporter-specific changes from the
human fetus to the adult.
No clear transporter-specific maturation pattern can
be deducted at this time, hence, further research is
needed.
Electronic supplementary material The online version of this
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1 Introduction
Plasma membrane transporters play an essential role in the
uptake of endogenous compounds into cells and their efflux
from cells. They also mediate the absorption, distribution,
and excretion of a large number of drugs [1, 2]. In par-
ticular, two major transporter superfamilies are the focus of
pharmacological studies: the adenosine triphosphate
(ATP)-binding cassette (ABC) transporters and the solute
carrier (SLC) transporter superfamilies [3, 4]. The
nomenclature is presented in Table 1. Numerous studies,
mostly in adults, have investigated altered membrane
transporter functions due to genetic variants or drug–drug
interactions by co-medications [1, 5–9]. Studies on the role
of membrane transporters in children are scarce, however.
Still, growth and maturation are likely to have an impact on
activity of these transporters in light of their role in
endogenous processes. Animal studies have indeed shown
developmental changes in membrane transporter expres-
sion [10]. The aim of this review is to present an up-to-date
overview on our current knowledge on the role of human
membrane transporters in pediatric drug disposition and
effect. For this purpose, a short overview of ex vivo studies
is presented after which results from pharmacokinetic and
pharmacogenetic studies of relevant membrane transporters
are reported that may broaden our insight into develop-
mental patterns for individual human membrane
transporters.
2 Ex Vivo Studies on the Ontogeny of Human
Membrane Transporters
Ex vivo data from pediatric samples may be used to
extrapolate existing adult pharmacokinetic data to children,
as is done using physiologically based pharmacokinetic
(PBPK) modeling [11, 12]. Expression patterns of mem-
brane transporters during human development have been
studied in postmortem and surgical tissue samples with the
use of different techniques such as immunohistochemistry
Table 1 Nomenclature of human membrane transporters: selection transporters discussed in this paper [source: NCBI Gene (http://www.ncbi.
nlm.nih.gov/gene)]
Gene Protein
Name Locus Name Synonyms
ABC transporters
ABCB1 7q21.12 ABCB1 MDR1, P-glycoprotein (P-gp), CLCS, PGY1, ABC20, CD243, GP170
ABCC2 10q24 ABCC2 MRP2, CMOAT, DJS, cMRP, ABC30
ABCC3 17q22 ABCC3 MRP3, MOAT-D, cMOAT2, MLP2, ABC31, EST90757
ABCC4 13q32 ABCC4 MRP4, MOAT-B, MOATB
ABCG2 4q22 ABCG2 BRCP, MXR, MRX, ABCP, BMDP, MXR1, BCRP1, CD338, GOUT1,
CDw338, UAQTL1, EST157481
SLC transporters
SLCO1B1 12p OATP1B1 OATP2, LST-1, OATP-C, HBLRR, LST1, SLC21A6
SLCO1B3 12p12 OATP1B3 OATP8, LST-2, LST3, HBLRR, SLC21A8, LST-3TM13
SLCO2B1 11q13 OATP2B1 OATP-B, SLC21A9
SLC3A2 11q13 4F2hc 4F2, CD98, MDU1, 4T2HC, NACAE, CD98HC
SLC22A1 6q25.3 OCT1 HOCT1, oct1_cds
SLC22A2 6q25.3 OCT2
SLC22A6 11q12.3 OAT1 PAHT, HOAT1, ROAT1
SLC22A7 6q21.1 OAT2 NLT
SLC22A8 11q11 OAT3
SLC15A1 13q32.3 PEPT1 HPEPT1, HPECT1
SLC47A1 17q11.2 MATE1
SLC47A2 17q11.2 MATE2-K MATE2, MATE2-B
Other
FAAH 1p35-p34 FAAH FAAH-1, PSAB
ADRB2 5q31-q32 ADRB2 BAR, B2AR, ADRBR, ADRB2R, BETA2AR
CDH17 8q22.1 HPT1 CDH16, LI cadherin
ABC adenosine triphosphate (ATP)-binding cassette, ADRB2 b2-adrenergic receptor, FAAH fatty acid hydrolase, SLC solute carrier
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to visualize tissue localization, reverse transcriptase poly-
merase chain reaction (RT-PCR) for messenger RNA
(mRNA) expression, Western blotting and new liquid
chromatography–tandem mass spectrometry (LC–MS/MS)
techniques to quantify transporter protein abundance. To
the best of our knowledge, transporter activity studies using
human pediatric tissue are non-existent. Although animal
data may provide valuable insight, potential developmental
patterns of membrane transporters in animals are likely to
differ from those in humans, as studies on drug metabo-
lizing enzymes (DMEs) have shown [13–15]. Moreover,
animal studies do not provide any information when there
are no direct orthologs in rodents, as is the case, for
example, for human organic anion-transporting polypep-
tide (OATP) 1B1 and OATP1B3.
From the embryonic and fetal period, most transporter
data result from immunohistochemistry and mRNA
expression studies. These data, often covering a small age
range and/or small sample size, suggest transporter-specific
maturation with a low fetal/neonatal or stable expression
pattern, but quantification is lacking [16–19]. The ex vivo
data from the first years of life consist mainly of hepatic
and intestinal mRNA expression data, with the inherent
limitation of a possible lack of correlation with protein
expression [20–24]. In children from 7 years onwards,
protein abundance data generated using LC–MS/MS have
been recently published [25–27]. Although a large pediatric
age range was covered by this project, the younger age
range, where most developmental changes are expected, is
lacking in protein abundance data.
The studies referenced above comprise the most sig-
nificant studies investigating the maturation of human
membrane transporters, with an emphasis on the clinically
relevant transporters ABCB1, ABCC2, OATP1B1, and
OATP1B3. The best-studied transporter during human
development is ABCB1 (Fig. 1). Interestingly, its devel-
opmental pattern seems organ-specific. In fetal intestinal
samples (16th to 20th week of gestation), ABCB1 could be
visualized [16] and intestinal mRNA data suggests
stable ABCB1 expression from the neonate up to the adult
[22, 24]. In the liver, mRNA expression data suggest a
pattern of low ABCB1 expression in fetuses, neonates, and
infants until 12 months of age, after which it increases to
adult levels [21, 22]. ABCB1 protein abundance measured
using LC–MS/MS was quite variable (4.8-fold) in 64
subjects in the age range 7–70 years, but this variation
could not be explained by either age or sex [25]. In fetal
human brain samples ranging from 7 to 28 weeks of ges-
tational age, ABCB1 immunostaining was detected in only
one sample from a 28-week fetus [16]. In contrast, in
postmortem central nervous system tissue from neonates
(n = 28) of 22–42 weeks of gestational age and from
adults (n = 3), immunohistochemistry showed increasing
ABCB1 staining with gestational age [28]. ABCB1 gene
expression was also detected in the brain of fetuses of 15,
27, and 42 weeks of gestational age [18]. Very recently, the
ABCB1 protein was shown to be limited at birth and to
increase postnatally to reach adult levels by 3–6 months of
age [29]. Renal ABCB1 mRNA expression appears to be
related to maturity of nephrons. A trend towards lower
expression in fetuses and neonates than in adults was
observed. ABCB1 protein has been identified as early as
the 5.5th week of gestation [16, 17, 21].
Fig. 1 Suggested ontogeny of
ABCB1 expression in intestine,
liver, kidney, and brain. ABC
adenosine triphosphate (ATP)-
binding cassette
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ABCC2 ontogeny shows similarities to ABCB1. Small
intestine ABCC2 mRNA expression is stable in neonatal
surgical patients compared to adults. While, hepatic
ABCC2 mRNA expression is much lower in the fetus,
neonate, and young infant (up to 200-fold lower) than the
adult [22, 27], in children from 7 years onwards its protein
expression appears stable [27]. On the protein level, both
the localization pattern and intensity of ABCC2 protein
staining appear to change during fetal life, in concert with
fetal liver maturation [19, 23].
Hepatic mRNA expression of OATP1B1 and OATP1B3
appears to show a different developmental pattern than
ABCB1 and ABCC2. Although fetal expression was 2- to
30-fold lower than adult expression, neonatal and infant
expression appeared to be even lower (up to 600-fold) [19,
22]. This pattern appears to be supported by protein data
(Western blotting) for OATP1B3 but not for OATP1B1. In
one study, OATP1B1 protein expression already appears at
adult levels in neonates, while in another OATP1B1 only
increases after the age of 6 years [30, 31]. Again, for both
OATP1B1 and OATP1B3, protein expression appears
stable at adult levels from 7 years onwards [25].
3 Pharmacokinetic and Pharmacogenetic Studies
of Relevant Membrane Transporter Substrates
Pharmacokinetic and pharmacogenetic studies may provide
insight into the impact of selected drug transporters in vivo.
We identified 16 drugs frequently prescribed to children
and that are known substrates of one or more specific
membrane transporters (Table 2; see the Electronic Sup-
plementary Material for the search strategy). Age-related
differences in pharmacokinetic or pharmacogenetic studies
may point to maturational changes in the transporter
involved. On the other hand, concordance between adult
and pediatric pharmacogenomic studies may support the
presence and potentially similar expression of the involved
transporters in children as in adults. To further support a
potential developmental pattern, we compared the in vivo
data with relevant ex vivo data of the individual trans-
porters. As many drugs are also substrates of DMEs and/or
multiple transporters, the presented data must be inter-
preted in the context of the interplay with metabolizing
enzymes. It can be speculated that when a specific DME is
developmentally low at a certain age, while the transporter
is already mature, this may impact the disposition of a drug
by potentially altering the absorption, distribution, meta-
bolism, and excretion (ADME) pathway from largely DME
based to transporter based. Where possible, we have only
included data that are highly supportive of a role for the
transporter(s) involved. Table 2 provides a summary of the
pharmacokinetic studies in children and the relationship
with transporters. For detailed genetic information on
individual transporters, the reader is referred to The Phar-
macogenomics Knowledgebase (www.pharmgkb.org) and
recent reviews [7, 8, 32–34].
3.1 Digoxin-ABCB1
The cardiac glycoside digoxin is a well-known ABCB1
substrate (Fig. 2). Its US Food and Drug Administration
(FDA) drug label warns about pharmacokinetic interactions
with intestinal or renal ABCB1 inducers or inhibitors.
Digoxin is mainly renally cleared as unchanged drug: 80 %
by glomerular filtration and 20 % by tubular secretion [35].
Pharmacokinetic studies in children show clear age-related
differences. In a population pharmacokinetic analysis in 71
neonates (age range 2–29 days), oral digoxin clearance
increased non-linearly with increasing bodyweight and
gestational age [36]. The estimated clearance of digoxin in
a term-born 3 kg newborn is 0.338 L/kg/h at a serum
concentration of 1 ng/mL. A population pharmacokinetic
study in older infants [n = 117, mean age (range) 0.76
(0.08–4.43) years] also found increased oral digoxin
clearance with increasing bodyweight [37]. In this study,
the simulated apparent oral clearance (CL/F) of an 8 kg
infant was 0.43 L/h/kg at a target concentration of 1 ng/
mL. Interestingly, digoxin clearance normalized for body-
weight appears to be much higher in term neonates and
younger children than in adults (0.17 L/h/kg). This obser-
vation is also in line with higher (per kg) dosing recom-
mendations in term neonates and infants. However, as the
drug is mainly renally cleared, and glomerular filtration is
still immature at birth, one would expect a lower body size-
corrected clearance. This was indeed the case in preterm
infants (\2.5 kg) whose digoxin bodyweight-corrected
clearance was much lower than that of term infants (0.064
vs. 0.1 L/h/kg), in line with lower dosing recommendations
for this age group [38]. Thus, in preterm newborns, both
the glomerular filtration rate (GFR) and ABCB1 may be
immature at birth, while in term infants ABCB1 activity
may already be more mature and compensate for devel-
opmentally low GFR.
Additionally, clearance decreases non-linearly with
increasing concentrations in the range of 0.2 and 2 ng/mL
in children up to 4.5 years of age, whereas non-linearity in
adults is only found from a serum concentration of 7 ng/
mL onwards. We can only speculate as to the underlying
mechanism. Earlier transporter saturation due to immature
ABCB1 activity in intestine and kidney contradicts the
observation of higher bodyweight-corrected clearance in
young children than in adults.
A clinically relevant interaction was found in eight
children who were co-administered the ABCB1 inhibitor
carvedilol. Digoxin clearance decreased twofold, while the
510 M. G. Mooij et al.
Table 2 Summary pharmacokinetic and pharmacogenetic studies of relevant membrane transporter substrates
Drug Relevant transporters involved
in transport of drug
PK and PGx results in children
Digoxin ABCB1 Higher bodyweight-corrected digoxin clearance in term neonates and young children
[36–38]. Renal clearance of digoxin in young children may be more dependent on
ABCB1-mediated tubular secretion than in adults [39]
Tacrolimus ABCB1 PGx studies of ABCB1 in relation to tacrolimus PKs appear contradictory [42, 43, 46,
47]. In pediatric liver transplant recipients, high intestinal ABCB1 mRNA
expression was associated with a twofold higher tacrolimus clearance [48]
Daptomycin ABCB1 Higher body size-corrected renal daptomycin clearance in neonates and younger
infants [51–53]
Fexofenadine OATP2B1, ABCB1, MRP2 Apparent bodyweight-corrected oral clearance was 1.5-fold lower in children
6 months to 6 years than in children 6–12 years [58]
Morphine OCT1, ABCB1, ABCC2,
ABCC3, OATP1B1
Neonates and infants have low morphine clearance in the first 10 days of life,
increasing thereafter, largely due to immature UGT2B7 metabolism, but
transporters may contribute [64, 65]. Neonates are more prone to morphine-related
respiratory depression [66]. ABCB1 genotype was associated with respiratory
depression in older children, in contrast to an adult study [62]. Also, ABCB1
genotype affects the M3G-formation and OCT1 genotype is associated with
variation in morphine clearance and glucuronide-metabolites formation [68]
Pravastatin OATP1B1, OATP2B1,
OATP1B3, ABCB1, ABCC2
Children with hypercholesterolemia and the SLCO1B1 –11187GA variant had lower
mean pravastatin AUCs than those with the wild-type, in contrast to an adult study
where the opposite effect was found [71, 72]. No age-related variability in
pravastatin PKs from children aged 5 years onwards [73]
Atorvastatin OATP1B1, BCRP Atorvastatin PKs in older children similar to adult PKs [74]
Bosentan OATP1B1, OATP1B3,
OATP2B1
In children, an exposure limit was found at a much lower dose than in adults, which
might be due to intestinal OATP2B1 saturation [80]
Ondansetron OCT1 Ondansetron PKs and clinical efficacy have been correlated with OCT1 genotypes in
adults [82]. Ondansetron clearance increased with age in children aged
1–48 months [83]
Metformin OCT, MATE1, MATE2 K Metformin PKs in children from 9 years of age onwards were comparable with adult
PKs, suggesting stable OCT and MATE activity [91]
Cimetidine OCT2, MATE1, MATE2 K,
OAT2
In neonates and children, cimetidine (and metabolites) renal clearance accounts for
80–90 % of total clearance, whereas in adults it accounts for 60 % of total
clearance [93–95]. The relatively high renal clearance suggests mature OCT2
activity at birth in the presence of immature GFR [99]
Tramadol OCT1 In adults, OCT1 genotype was related to metabolite plasma concentrations and
prolonged miosis [101]. Tramadol and metabolite PKs show age-related changes in
neonates [102]
Methotrexate OATP1B1, ABCC2 Increased renal toxicity in children 0–3 months old compared with infants
7–12 months [106]. From 1 year of age onwards, body size-corrected methotrexate
clearance decreased linearly with age [107]. SLCO1B1 genotype was associated
with increased AUC and was a predictor for toxicity [107]
Mycophenolate
mofetil
MRP2 In pediatric patients, ABCC2 rs717620 allele has been associated with reduced
exposure to MPA, more adverse effects, and rejection [114]
Acyclovir/valacyclovir 4F2hc, HPT1, OAT1, OAT3 In neonates, the IV acyclovir bodyweight-corrected clearance showed a twofold
increase from 25 to 41 weeks of gestational age [118]. In older children, 1 month to
5 years, apparent oral clearance of valacyclovir in children less than 3 months of
age was 50 % than that in older children [119]
Adefovir OAT1, MRP4 Adefovir is partly renally cleared (45 %) [120, 121]. In 45 children (age range
2–17 years) receiving oral adefovir dipivoxil, weight-corrected mean apparent
clearance and renal clearance were higher in younger children [122]
ABC adenosine triphosphate (ATP)-binding cassette, AUC area under the plasma concentration–time curve, BCRP breast cancer resistance
protein, GFR glomerular filtration rate, HPT human oligopeptide transporter, IV intravenous, M3G morphine-3-glucuronide, MATE multidrug
and toxin extrusion protein, MPA mycophenolic acid, mRNA messenger RNA, MRP multidrug resistance-associated protein, OAT organic anion
transporter, OATP organic anion-transporting polypeptide, OCT organic cation transporter, PGx pharmacogenetics, PK pharmacokinetic, UGT
uridine 50-diphospho-glucuronosyltransferase
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digoxin clearance to GFR ratio decreased by 45 %, sup-
porting intestinal and renal ABCB1-mediated inhibition
[39]. In contrast, the same drug–drug interaction resulted in
only a mild decrease in digoxin clearance in adults. These
findings support our hypothesis that renal clearance of
digoxin in young children may be more dependent on
ABCB1-mediated tubular secretion than in adults.
Interestingly, the hypothesis of higher renal ABCB1
expression after birth is supported by a mouse study
showing a relationship between renal Abcb1 expression
Fig. 2 Membrane transporters and their relationship with commonly
prescribed drugs to children: digoxin, tacrolimus, morphine, pravas-
tatin, and atorvastatin. ABC adenosine triphosphate (ATP)-binding
cassette, CYP cytochrome P450, OATP organic anion-transporting
polypeptide, OCT organic cation transporter, UGT uridine 50-diphos-
pho-glucuronosyltransferase
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and digoxin clearance in young mice, but not by the limited
human data from neonates [21, 40].
3.2 Tacrolimus-ABCB1
The calcineurin inhibitor tacrolimus inhibits synthesis of
cytotoxic lymphocytes and so prevents transplant rejection.
Tacrolimus is a substrate for intestinal and hepatic ABCB1
(Fig. 2) [41]. Weight-normalized oral tacrolimus clearance,
which is also dependent on cytochrome P450 (CYP) 3A4/5
metabolism, is higher in infants between 1 and 6 years of
age than in older children and adults [42, 43]. CYP3A4
activity matures in the first year of life, while CYP3A5
activity, when present, appears stable from fetus to adult
[44].
Pharmacogenetic studies of ABCB1 in relation to
tacrolimus disposition appear contradictory [45]. In pedi-
atric heart and kidney transplant recipients no relation was
found between ABCB1 genotype and tacrolimus dosing
requirements or concentration/dose ratio [42, 43]. In
pediatric liver transplant patients, homozygous ABCB1
1236TT/2677TT/3435TT carriers needed higher tacrolimus
doses than non-carriers both early and later after trans-
plantation [42, 46]. In a population pharmacokinetic anal-
ysis in 114 pediatric liver transplant recipients, the ABCB1
2677G[T allele was associated with a higher pre-dose and
concentration/dose ratio at day 1 after transplantation [47].
Such associations were not found for recipient or donor
ABCB1 1199G[A and 3435C[T variants. These findings
can be understood from a combined ex vivo/population
pharmacokinetic study in 130 pediatric liver transplant
recipients. High intestinal ABCB1 mRNA expression was
associated with an almost twofold higher tacrolimus
clearance early after transplantation, indicative of a switch
from primarily intestinal to hepatic tacrolimus clearance
upon graft recovery [48].
The results from ex vivo studies suggesting
stable ABCB1 mRNA intestinal expression and lower
hepatic ABCB1 expression in young infants may explain
the pharmacogenetic findings and the impact of the recip-
ient intestinal ABCB1 on tacrolimus disposition [20, 22,
24, 48].
3.3 Daptomycin-ABCB1
The antibacterial daptomycin is used to treat infections
caused by Gram-positive bacteria including methicillin-
resistant Staphylococcus aureus (MRSA). Daptomycin is
excreted primarily by the kidney and is an ABCB1 sub-
strate. In 23 adult Caucasian patients, the ABCB1 3435T
single nucleotide polymorphism (SNP) was associated with
a higher intravenous daptomycin dose-normalized area
under the plasma concentration–time curve (AUC) and
lower steady state clearance [49, 50]. In 24 children (age
range 3–24 months), intravenous daptomycin clearance in
younger infants (approximately 20 mL/h/kg) was higher
than previously reported for older children and adults
(8–13 mL/h/kg) [51, 52]. Likewise, in 20 preterm and term
infants (32–40 weeks of gestational age and 0–85 days’
postnatal age, the mean clearance was approximately
20 mL/kg/h) [53]. No relationship with gestational or
postnatal age was found, possibly due to the small sample
size. The maturation pattern of daptomycin pharmacoki-
netics resembles that of digoxin pharmacokinetics, with
higher clearance values early in life. This pattern is not
consistent with immature GFR, but may reflect a com-
pensatory role of ABCB1-mediated renal tubular secretion
in young children. As discussed earlier, this may be the
result of increased renal ABCB1 expression in young
infants, but these findings need to be confirmed [16, 18,
21].
3.4 Fexofenadine-OATP2B1
The antihistamine fexofenadine is mainly excreted through
bile as parent drug. Only a minor part is metabolized by
intestinal microflora and CYP3A4. Its disposition appears
to be subject to membrane transport by the uptake trans-
porter OATP2B1, the efflux transporter ABCB1, and pos-
sibly ABCC2 [54–56]. In 14 healthy men, fexofenadine
clearance was related to OATP2B1 polymorphisms and
simultaneous apple juice ingestion [57]. This latter finding
of a potential food–drug interaction concerning OATP2B1
substrates may be even more relevant for children, as
heavy consumers of apple juice. In a population pharma-
cokinetic study in 515 Japanese children (6 months to
16 years), CL/F was stable across the age groups (1 L/h/
kg) with the exception of the 6- to 12-year-olds, whose
clearance was 1.5-fold higher (1.5 L/h/kg) [58]. In another
population pharmacokinetic study including 46 Caucasian
and 31 non-Caucasian children (6 months to 12 years) and
138 adults, apparent bodyweight-normalized oral clearance
was lower in children less than 1 year of age than in older
children and adults [59]. Interestingly when comparing
ethnicities, the CL/F was slightly higher in the 6- to
12-year-old Japanese children (1.5 L/kg/h) than in 14 non-
Japanese children (0.8 L/h/kg) (13 Caucasian and one non-
Caucasian), but this difference may be due to the small
sample size rather than ethnicity [58].
Ex vivo data in these age groups are lacking, but
OATP2B1 gene expression in 15 neonatal intestinal sam-
ples obtained during surgery was nearly three times higher
than in adult samples [22]. This may imply higher oral
absorption of fenofexadine in neonates and young infants.
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3.5 Morphine-ABCB1 and OCT1
The opioid morphine is almost completely metabolized by
uridine 50-diphospho-glucuronosyltransferase (UGT) 2B7
and UGT1A1 to morphine-3-glucuronide and morphine-6-
glucuronide. The disposition of both morphine and/or its
metabolites is subject to membrane transport by the uptake
transporters organic cation transporter (OCT) 1 and
OATP1B1 and by the efflux transporters ABCB1, ABCC2,
and ABCC3 (Fig. 2) [60, 61]. Hepatic uptake of morphine
appeared to be OCT1-mediated in an adult volunteer study
and carriers of loss-of-function SLC22A1 gene polymor-
phisms showed higher morphine AUCs [61]. In other
healthy adult volunteers, co-administration of the ABCB1
inhibitor quinidine altered both morphine pharmacokinet-
ics and its opioid effects after oral but not after intravenous
morphine administration, suggesting a limited role for
ABCB1 in the disposition of morphine at the liver and
blood–brain barrier [62]. In adult cancer patients receiving
oral morphine, pain relief was more prominent in
homozygous carriers of the ABCB1 3435T/T SNP, proba-
bly due to higher intestinal uptake [63].
Age-related morphine clearance in neonates and infants
is very low in the first 10 days of life and increases
thereafter [64]. Although this pattern was explained by
UGT2B7 maturation, an impact of the maturation of the
relevant transporters cannot be ruled out. Interestingly, in
follow-up studies in which morphine doses were adjusted
to the age-related clearance and similar exposure was
reached across the first year of age, pain relief was ade-
quate in neonates (\10 days of age), but the older children
still needed high doses of rescue morphine [65]. Neonates
are more prone to respiratory depression, which may be
explained by increased exposure to morphine when doses
are not adjusted to the age-related changes in its disposi-
tion. In addition, immature ABCB1 activity at the blood–
brain barrier, as shown very recently, cannot be ruled out to
contribute as well and deserves further study [29].
Sadhasivam and co-workers [66, 67] have extensively
studied the impact of genetics of transporters in a large
cohort of infants and children receiving intravenous mor-
phine for tonsillectomy. In 220 infants, OCT1 homozygous
genotypes (SLC22A1 1365GAT[del/1498G[C) were
associated with lower morphine clearance and lower mor-
phine glucuronide formation [68]. ABCC3 homozygous –
211 CC carriers showed (approximately 40 %) higher
metabolite transformation, indicating increased efflux of
metabolites into plasma. ABCB1 polymorphisms (3435
C[T) only affected morphine-3-glucuronide formation, not
morphine or morphine-6-glucuronide pharmacokinetics. It
should be noted that only pharmacokinetic data up to
45 min post-dosing were available and, hence, the full
pharmacokinetic profile of morphine and its metabolites
could not be determined. In 263 children of the same
cohort, the ABCB1 G allele of the rs9282564 polymor-
phism was associated with respiratory depression, resulting
in prolonged hospital stay (odds ratio 4.7; 95 % confidence
interval 2.1–10.8, P = 0.0002) [66]. This study contrasts
with the adult study in which ABCB1 inhibition did not
influence the effect of morphine after intravenous admin-
istration [62]. In the extended cohort, now including 347
children, the interaction of genetic variants of ABCB1 and
two other genes, the fatty acid hydrolase (FAAH, which has
been associated with opioid use and addiction acting via
cannabinoid receptor type 1), and the b2-adrenergic
receptor (ADRB2, receptor blockade has been associated
with pain and pain relief), helped discriminate low and
high risk for morphine-related postoperative respiratory
depression [67].
As hepatic ABCB1 gene expression only appears to
reach adult levels after the first year of life [20, 22, 24, 48],
immature hepatic and possibly also blood–brain barrier
ABCB1 expression may play a role in higher morphine
plasma and brain exposure and the higher risk for respi-
ratory depression in neonates.
3.6 Pravastatin-OATP1B1
Clearance of the cholesterol synthesis inhibitor pravastatin
is mainly dependent on non-CYP450-mediated drug
metabolism and several uptake and efflux transporters,
such as OATP1B1, OATP2B1, OATP1B3, ABCB1, and
ABCC2 (Fig. 2) [69]. In adults, SLCO1B1, but not ABCC2,
ABCB1, or ABCG2, gene variants were associated with
inter-individual variability in pravastatin pharmacokinetics,
suggesting a major role of SLCO1B1 in pravastatin dis-
position [70, 71].
Intriguingly, in one small pharmacogenetic study
(n = 20; mean ± standard deviation age 10.3 ± 2.9 years),
children with familiar hypercholesterolemia with the
SLCO1B1 –11187GA genotype had lower mean pravastatin
AUCs than children with the wild type [72]. The opposite
effect was found in an adult study (n = 41) [71]. These
results, which should be interpreted with care in view of the
small sample size, suggest age-related post-translational
differences in OATP1B1 expression. The pharmacokinetics
of pravastatin in children (aged 5–16 years) were similar to
adults, which suggests no major impact of age-related vari-
ability in OATP1B1 or other transporter activity from
5 years onwards [73]. These results appear to be in line with
the ex vivo results of stable hepatic OATP1B1 expression in
older children [25].
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3.7 Atorvastatin-OATP1B1
Another cholesterol synthesis inhibitor increasingly used in
children is atorvastatin. Like the other statins (HMG-CoA
reductase inhibitors), atorvastatin is extensively metabo-
lized, largely by CYP3A4, and is a substrate for OATP1B1
(hepatic uptake) and ABCG2 (oral absorption) (Fig. 2). In
a population pharmacokinetic study in pediatric hyperc-
holesterolemia patients aged 6–17 years, atorvastatin CL/
F was described as a function of bodyweight. When scaled
allometrically, CL/F was similar to values reported for
adults [74]. Atorvastatin metabolism is probably mature
from 6 years onwards. The stable clearance and the exist-
ing ex vivo data of OATP1B1 suggest similarly mature
transporter activity, although an age-related change in the
relative contribution of individual transporters cannot be
ruled out [25, 26]. We could not identify pediatric phar-
macogenetic atorvastatin studies, although a comprehen-
sive study in adults clearly indicated the SLCO1B1 variant
388A[G as a major determinant for atorvastatin pharma-
cokinetics [75].
3.8 Bosentan-OATP2B1
Bosentan is metabolized by CYP3A4 and CYP2C9, with
both the parent compound and one metabolite being phar-
macological active, but is also subject to hepatic uptake by
OATP1B1, OATP1B3, and maybe OATP2B1 [76]. Next to
the developmental pattern of CYP3A4, CYP2C9 already
shows an increase prenatally, with stable, though variable,
activity after the first week of postnatal age [77, 78]. Hence,
the impact of the maturation of the transporters may be
compounded by CYP3A4 and CYP2C9 maturation in the
first year of life, but age-related variation as observed later in
life may be more likely due to transporter maturation. At oral
doses of approximately 2 mg/kg, bosentan plasma exposures
for 19 children (aged 3–15 years) were similar to those for
healthy adults [79]. In children [n = 36, median (range) age
7.0 (2–11) years], plasma concentrations did not further
increase at doses higher than 2 mg/kg (exposure limit), while
in adults the exposure limit was 7 mg/kg, with no difference
in the other pharmacokinetic parameters [80]. As bosentan
appears to be an OATP2B1 substrate, intestinal saturation
due to immature OATP2B1, and perhaps other anatomical or
physiological age-related differences in oral absorption, may
explain this observation. This result does not correspond
with the OATP2B1 mRNA expression results, suggesting
higher expression in neonates than in adults [22]. In a pedi-
atric population pharmacokinetic–pharmacogenetic study
[n = 46, mean (range) age 3.8 years (25 days–16.9 years)],
no relationship between bosentan pharmacokinetics and
genetic polymorphisms of SLCO1B1, SLCO1B3, SLCO2B1,
or CYP3A5 was found [81].
3.9 Ondansetron-OCT1
The anti-emetic ondansetron is mainly metabolized by
CYP2D6, which contributes to genetic variation in its
disposition and effect. In addition to this CYP2D6 effect,
the pharmacokinetics (n = 45) and clinical efficacy
(n = 222) of ondansetron in adults (age range
18–83 years) have also been correlated with SLC22A1
genotypes [82]. OCT1 deficiency potentially limits the
hepatic uptake and increases plasma concentrations of
ondansetron [82]. In a population pharmacokinetic analysis
of 124 patients in the age range 1–48 months, ondansetron
bodyweight-normalized clearance was reduced by 76 % in
a 1-month-old patient and by 31 % in a 6-month-old
patient, compared with the older children [83]. This con-
trasts with evidence from both in vitro and in vivo studies
suggesting maturity of CYP2D6 activity as early as
1–12 weeks postnatal [84–86]. Thus, we hypothesize that
lower ondansetron clearance in the first year of life may be
related to immature OCT1 activity.
3.10 Metformin-OCT1 and MATE1
Several transporters have been implicated in metformin
elimination, tissue distribution, and response. OCT1 is a
major determinant of the hepatic uptake of metformin,
while multidrug and toxin extrusion protein (MATE) 1/
MATE2-K determine the efflux of metformin [7, 34].
Recently, the transcription factor hepatocyte nuclear factor
1 was found to regulate OCT1 expression and was related
to metformin pharmacokinetics and pharmacodynamics
[87, 88]. The combination of SLC22A1 (OCT1) and
SLC47A1 (MATE1) genotypes further explains variation in
response to metformin in adults [8, 89]. In contrast, in 140
non-obese adolescent girls with androgen excess after
precocious pubarche, SLC22A1 genotype was not related to
metabolic response at 1 year of metformin treatment [90].
In non-obese 9-year-old girls and diabetic patients aged
12–16 years, pharmacokinetics were comparable with
those in adults [91, 92]. This suggests stable OCT1 or
MATE activity from the age of 9 years onwards, but this
needs further study, especially since data in younger chil-
dren are lacking.
3.11 Cimetidine-OCT2
In adults, renal excretion of the histamine H2-receptor
antagonist cimetidine and its metabolites accounts for
60 % of total clearance, versus 80–90 % in children and
neonates [93–95]. Cimetidine is partially metabolized and
is a substrate of the uptake transporters OCT2 and organic
anion transporter (OAT) 2 and the efflux transporters
MATE1 and MATE2-K [8, 34, 96, 97]. Cimetidine is a
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well-known OCT2 inhibitor and therefore could potentially
counteract OCT2-driven cisplatin oto- and renal toxicity
[98]. Although the drug is now rarely used in pediatric
clinical care, this latter promise necessitates a full under-
standing of its disposition across the pediatric age range, as
part of studies to confirm this new indication. The rela-
tively high renal clearance in neonates and children sug-
gests an important role for renal tubular secretion and
suggests mature activity already at birth. On the other hand,
Ziemniak et al. [94] suggest that the unexplained gap
between total and renal clearance in adults could be due to
secondary metabolite formation in adults, which maybe
missing in neonates due to immature metabolism. This is
less likely, however, as the higher renal clearance was also
observed in older children, whose drug metabolism is lar-
gely at adult levels. Moreover, in a rat study, bile duct
ligation increased cimetidine renal tubular secretion by up-
regulation of OCT2 (but not MATE1), supporting the
hypothesis that the non-renal clearance in adults occurs
through hepatic/bile excretion and is not related to
unknown secondary metabolite formation [99]. Neverthe-
less, as analytical methods to measure drugs and metabo-
lites have become more sensitive since the early studies in
the mid-1980s, new studies in children of different ages
could help elucidate why renal clearance of cimetidine
differs between children and adults and give insight into
the role of OCT2 in cimetidine disposition.
3.12 Tramadol-OCT1
Tramadol is a prodrug of the l-opioid receptor agonist O-
desmethyltramadol. It is metabolized mainly by CYP2D6
to its active O-desmethyltramadol metabolite [100]. The
variation in tramadol pharmacokinetics cannot solely be
explained by variation in CYP2D6, as was shown by
Tzvetkov et al. [101] who showed an additive effect of
OCT1 on tramadol disposition variation. Loss-of-function
SLC22A1 polymorphisms have been related to higher
plasma concentrations of the active O-desmethyltramadol
and prolonged miosis, as a surrogate marker of the opioid
effect. These effects are likely due to reduced OCT1-me-
diated hepatic uptake [101]. Allegaert and co-workers
[102] showed that maturational clearance of tramadol,
driven by CYP2D6 activity, is almost complete by
44 weeks post-menstrual age. In a pooled population
pharmacogenetics–pharmacokinetic study covering the age
range from preterm to elderly, only part of the variability in
O-desmethyltramadol formation clearance could be
explained by the CYP2D6 genotype, further supporting a
potential role for SLC22A1 genetic variation [86]. A rela-
tionship between CYP2D6 genotype and tramadol meta-
bolism was shown in young preterm infants, which is
surprising as CYP2D6 is not fully mature at birth,
especially not in preterm infants, and a genotype effect
may have been obscured. It would be worthwhile, there-
fore, to study the impact of the SLC22A1 genotype in this
young population [10]. In a population pharmacokinetic/
pharmacodynamic analysis of 104 older children
(2–8 years), age did not clearly contribute to variation in
pharmacokinetics or the prediction of response [103].
3.13 Methotrexate-OATP1B1 and ABCC2
Methotrexate is a folic acid antagonist used to treat several
forms of cancer and anti-inflammatory diseases.
Methotrexate undergoes complex hepatic and intracellular
metabolism [104]. Many membrane transporters are
responsible for its uptake and excretion and for its meta-
bolism to active polyglutamine metabolites and inactive
7-hydroxy-methotrexate [104, 105]. Methotrexate is elim-
inated primarily by renal excretion through glomerular
filtration and renal tubular reabsorption and secretion.
Approximately 70–90 % of a dose is excreted unchanged
in urine. A small pharmacokinetic study showed only
marginally lower methotrexate steady-state clearance
(body surface area corrected), but increased renal toxicity,
in 0- to 3-month-old infants than in 7- to 12-month-old
infants [106, 107]. From 1 year of age onwards,
methotrexate clearance (body surface area normalized)
decreased linearly with age [107]. A 2014 review con-
cluded that ‘‘although there is no pharmacogenetic marker
for MTX [methotrexate] in use in the clinic at present,
polymorphisms in SLCO1B1 have an important role in
MTX pharmacokinetics and toxicity in pediatric ALL
[acute lymphoblastic leukemia] patients and show the most
consistent and promising results’’ [105]. For example, in a
cohort of almost 500 pediatric acute lymphoblastic leuke-
mia (ALL) patients, the methotrexate AUC from time zero
to 48 h (AUC48) increased by 26 % (P\ 0.001) per
SLCO1B1 rs4149056 C allele and was a significant pre-
dictor of overall toxic adverse events during methotrexate
courses (R2 = 0.043; P\ 0.001), but no relationship was
found for ABCC2 [107]. This study confirmed the results of
a genome-wide association study (GWAS) in 434 ALL
children, the first to identify SCLO1B1 genetic variation as
an important marker of methotrexate pharmacokinetics and
clinical response, and was recently validated by five dif-
ferent treatment regimens of high-dose methotrexate in
ALL treatment protocols at St Jude Children’s Research
Hospital (Memphis, TN, USA) [108]. Moreover, a deep
sequencing approach for SLCO1B1 demonstrated that rare
damaging variants contributed significantly to methotrex-
ate clearance and had larger effect sizes than common
SLCO1B1 variants [109, 110]. Other recent studies have
detected a relationship between ABCC2 and methotrexate
pharmacokinetics and toxicity. In 112 Han Chinese
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pediatric ALL patients, the ABCC2 –24T allele (rs717620)
was associated with significantly higher methotrexate
plasma concentrations at 48 h and with significant hema-
tological and non-hematological toxicities. These findings
are partially supported by other studies in 127 Lebanese
and 151 Spanish pediatric ALL patients [111, 112].
3.14 Mycophenolate Mofetil-ABCC2
Mycophenolate mofetil is the prodrug of the active
mycophenolic acid (MPA). It is metabolized by car-
boxylesterase 2 (CES2), after which MPA is further
metabolized by several CYPs and UGTs [113]. MPA-glu-
curonide is excreted in the bile primarily by ABCC2 (en-
coded by ABCC2) and this transport is essential for
enterohepatic circulation. The ABCC2 rs717620 A allele
has been associated with reduced exposure to MPA in
pediatric renal transplant recipients [114]. In a large mul-
ticenter cohort of pediatric heart transplant recipients,
ABCC2 rs717620 A allele was also associated with more
gastrointestinal intolerance, but with fewer short- and long-
term rejection episodes [114]. As ABCC2 is thought to
excrete MPA-glucuronide in the bile, carriers of the active
A allele, may have increased enterohepatic circulation with
an increased concentration of free MPA in the intestine.
This is potentially associated with more gastrointestinal
intolerance, but simultaneously with higher exposure and
efficacy. As SNPs in UGT1A9, UGT2B7, SLCO1B3, and
IMPDH have also been associated with altered MPA
exposure, the combined effect of these SNPs and poten-
tially interacting co-medication, may define high- and low-
risk patients for MPA efficacy and toxicity. Full hepatic
ABCC2 maturation appears to occur after infancy, sug-
gesting a lower enterohepatic circulation of MPA, which
may result in less gastrointestinal intolerance but poten-
tially also with less efficacy in this age group [22]. This is
merely a hypothesis without confirming pharmacokinetic
data.
3.15 Acyclovir/Valacyclovir-OAT1 and OAT3
The oral bioavailability of the anti-viral agent acyclovir is
poor, and therefore its prodrug valacyclovir was developed.
A positive association was found between intestinal
expression of 4F2hc (SLC3A2, amino acid transporter
heavy chain, a membrane glycoprotein), and HPT1 (human
oligopeptide transporter) and plasma levels of valacyclovir,
but not peptide transporter 1 [PEPT1 (SLC15A1)] or any of
the other investigated intestinal organic anion or cation
transporters [115].
After hepatic metabolism, both drugs are mainly renally
excreted by both glomerular filtration and renal tubular
secretion, most likely by OAT1 and OAT3 [116, 117]. In
preterm and term neonates (n = 28, median age 30 weeks
of gestation), the intravenous acyclovir bodyweight-cor-
rected clearance showed a twofold increase from 25 to
41 weeks of gestational age [118]. In children 1 month to
5 years old with or at risk for herpes infection, the CL/F of
valacyclovir (mL/kg/min) in those younger than 3 months
was 50 % of that in older children, in whom bodyweight-
corrected clearance remained stable [119]. A recent study
showed markedly increased acyclovir concentrations when
co-administered with benzylpenicillin, which was shown to
be due to OAT3 and possibly OAT1 inhibition [116]. This
could be a very relevant interaction in septic newborns,
who often receive both drugs, as increased acyclovir con-
centrations are associated with neurological adverse events
as well as neutropenia.
3.16 Adefovir-OAT1 and ABCC4
Adefovir, the antiviral agent used for treatment of hepati-
tis B virus or HIV, is 45 % renally cleared through
glomerular filtration and OAT1/ABCC4 renal tubular
secretion [120, 121]. In 45 children in three age groups
(2–6, 7–11, and 12–17 years) receiving oral treatment for
hepatitis B virus with the prodrug adefovir dipivoxil,
bodyweight-corrected mean apparent clearance and renal
clearance were decreasing with increasing age [122].
Similarly, in a phase I study in children (n = 13, age range
6 months to 18 years) receiving oral adefovir dipivoxil for
HIV treatment, systemic exposure was lower in children
younger than 5 years [123].
4 Summary and Discussion
In summary, ex vivo, pharmacokinetic and pharmacogenetic
studies suggest transporter-specific changes from the human
fetus to the adult. At this time, data are very scarce and the
impact of these changes on drug therapy in children is still
largely unknown. However, despite data scarcity, our review
may aid clinical pharmacologists and clinicians in rationale
drug prescribing of the drugs presented, not only by showing
how pharmacokinetics are probably similar in certain pedi-
atric age groups compared to adults, but also by pointing out
where potential age-related changes in individual trans-
porters could impact the drug’s efficacy and safety. It
broadens our views on ontogeny of transporters by evalua-
tion of the results of pharmacokinetic and pharmacogenetic
studies on relevant transporters. Moreover, this review pre-
sents clear information gaps, which may guide future
research efforts to elucidate the role of human membrane
transporters in the developing child.
For most drugs, the in vivo data to support the ex vivo
data in understanding the maturation of individual
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transporters are limited to older children, and, hence, their
usefulness is limited. No clear transporter maturation pat-
tern can be deducted from any of the available pharma-
cokinetic studies in children. This contrasts with our
knowledge from individual DMEs. For example, using
midazolam as a phenotyping probe, the developmental
expression of CYP3A4/5 from the preterm neonate to the
adult has been extensively characterized [124, 125] as has
amikacin clearance to display the maturation of GFR in
neonates [125]. Specific phenotyping probes to study
individual membrane transporters are suboptimal and have
only been validated in adults. For many drugs, multiple
transporters are involved in their uptake and excretion,
which in turn may also compensate for changes in indi-
vidual transporter activity. In adults, knowledge has also
been gained from pharmacogenetic and drug–drug inter-
action studies.
This review shows that pharmacogenetic variation in
membrane transporter activity also impact drug disposition,
effect, and toxicity in children. Most pharmacogenetic
studies in children are in line with adult data. However,
these similar pharmacogenetic relationships should be
interpreted with care, especially when it comes to trans-
lating these data across the whole pediatric age range. First,
most pharmacogenetic study cohorts only contain older
children, whereas pharmacokinetic studies in neonates and
infants often show clear developmental changes up to
4–6 years of age. Hence, the impact of SNPs may be
obscured by more prominent changes due to growth and
development. Second, the relationship between SLCO1B1
SNPs and pravastatin disposition in adolescents was found
to be the opposite of that in adults. If these results are
validated in other studies, a potential impact of hormonal
changes on individual transporters needs to be elucidated;
this may also provide insight into the physiological role
these transporters play during adolescence.
The limited data from ex vivo studies of postmortem or
surgical samples support the notion of membrane trans-
porter-specific maturational patterns. It is still difficult,
however, to determine definitive patterns for the different
transporters. One of the reasons for this is that most studies
only used limited samples and limited age ranges. Most
fetal and neonatal studies only applied immunohisto-
chemistry or mRNA techniques, while the more quantita-
tive protein expression data are mainly from older children,
above the age range in which most developmental changes
can be expected. In addition, the quality and interpretation
is further challenged as the exact origin, handling, and
storage of tissues, including detailed patient characteristics
and exact procurement site from organ (e.g., where in the
intestine?), is often unknown.
The mechanisms underlying maturational changes in
transporters are largely unknown. Recent studies on
CYP3A4 show maturational changes in methylation pat-
terns to mirror the maturational expression of CYP3A4,
which may point towards similar mechanisms for the
transporters [126].
Differences between ethnic groups in DME abundance
or ethnicity have been described, even in newborn infants
[77, 85, 127]. Like in DMEs, it is credible to believe that
ethnicity might have an effect on transporter activity or
abundance. Nevertheless, for 27 drug transporters in 95
pathologically normal kidney samples, the expression did
not differ between European Americans or African
Americans [128].
The interpretation of pharmacokinetic studies, to
understand maturation of transporters, is complicated by
the fact that these transporters are part of the larger system
of the ADME processes involved in the disposition of
drugs. In contrast to DMEs, where clearance to a specific
metabolite can be estimated to understand the DME mat-
uration, studying a single transporter is more difficult. One
may not be able to pinpoint one specific membrane trans-
porter involved, and if the dominant transporter is still
immature early in life, other transporters may compensate,
thereby obscuring individual transporter maturation.
5 Future Directions
Several approaches are needed to increase our under-
standing of membrane transporters in the fetus and child
(Table 3). First, the impact of transporter maturation on
efficacy and toxicity in daily clinical care needs to be
elucidated. Pharmacogenetic studies can be a powerful tool
to this aim, provided they have adequate power and vali-
dation cohorts, the lack of which is a major limitation of
currently published studies. Studies need to not only be
powered to study the impact of a single SNP in one
transporter gene, but at the least, the interaction with age
should be part of their designs. Preferably such studies
should be designed to study the disposition of a drug in the
context of systems pharmacology, also including SNPs in
other relevant pharmacokinetic and/or pharmacodynamic
genes, as well as pharmacokinetic sampling enabling the
separation of different excretion pathways (e.g., GFR vs.
tubular secretion vs. bile secretion vs. metabolism). In
addition to pharmacogenetic studies, well-designed studies
reflecting clinical drug–drug interaction scenarios may
improve our understanding of transporter maturation, such
as pharmacokinetic studies in which patients’ samples are
taken before/during/after co-medication with a potentially
interacting drug. For example, the carvedilol–digoxin study
[39] or the older cimetidine studies in neonates in which
renal clearance by glomerular filtration could be separated
from renal tubular secretion [94], have, by their design,
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provided support for age-related differences in specific
renal transporters.
Ethical challenges have limited studies in infants and
neonates. However, many drugs in our review are regularly
prescribed, even for these young children. Therefore,
opportunistic sampling or biobanking of left-over samples
from children who take these drugs for therapeutic reasons
may aid overcoming these ethical barriers.
At this time, endogenous markers to phenotype the
activity of individual transporters are lacking. With the
increased availability of metabolomics, specific metabo-
lites or metabolite ratios may be identified to reflect
transporter activity in vivo. A recent GWAS–metabolomics
study detected specific metabolites/metabolite ratios for
selected transporters such as OCT1 [129–133]. The feasi-
bility of this approach was recently shown for CY2D6
phenotyping in children [129]. To design drug-dosing
regimens in children, population PBPK models are
increasingly being used [134]. Modeling and simulation
can be used in different ways to increase our understanding
and to design dosing regimens. Using a systems approach,
modeling of the disposition of a substrate model drug can
result in a mathematical description of the maturation of
the specific transporter. This maturational description can
then be used to simulate dosing guidelines for other
transporter substrates. The feasibility of this approach has
been used to describe maturation of selected DMEs and
GFR clearance [133, 135]. Secondly, PBPK modeling,
which incorporates available drug property and physio-
logical information, could be used to simulate the impact of
maturation of specific transporters, preferably with actual
ex vivo data on transporter expression/activity [134]. An
example is a mechanistic PBPK model to predict morphine
levels in breast-fed neonates of codeine-treated mothers
[136]. A major limitation of these models is the lack of
high quality ex vivo data on transporter activity across the
pediatric age range and the lack of in vivo validation of
these models.
In the design of new studies, the following issues should
be considered. The collection of these data can only be
achieved by an international effort to collect high-quality
tissue in collaboration with surgeons, pathologists, ethi-
cists, clinical researchers, and experts in drug transporter
research. The limitations of current tissue collections have
been described here and good protocols for tissue collec-
tion, preferably in the context of internationally accessible
biobanks, should be developed. Newer laboratory tech-
niques should be strongly considered to minimize tissue
amounts needed, for example, for laser capture and LC–
MS/MS to determine protein abundance. Moreover, a
multi-omics approach, including not only genomics but
also transcriptomics, proteomics, metabolomics, and
microbiomics, may provide greater power to predict drug
efficacy and adverse drug reactions [137, 138]. Also, with
the fast developments in tissue engineering, the current
ethical and practical issues regarding tissue sampling and
storage could be overcome using pediatric-engineered tis-
sues. This may even enable transporter activity studies,
which are now not available in pediatric tissue.
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Table 3 Approaches to future transporter studies
Ex vivo research
Build multidisciplinary research teams for tissue collection and
study design, e.g., surgeons, pathologists, clinical study staff,
basic researchers
Use optimal age distribution, e.g., tissues samples from fetuses,
neonates, and young infants, where most developmental changes
can be expected, as well as sample number to ensure adequate
power to detect age-related changes
Establish high-quality tissue collections with detailed tissue
handling description and detailed description of patient
characteristics
Use protein quantification techniques (e.g., LC–MS) and develop
tools to study activity with minimal amounts of human tissue
PK studies
Phenotyping studies with drugs that are clinically used, and
consider microdosing studies
Blood sampling at similar times as clinical blood draws
(opportunistic sampling)
Perform population PK analyses
Design drug–drug interaction studies
PGx studies
In pediatric populations, test genetic variants in transporters
known to affect PKs or PDs in adults
Take into account PGx variation in affected drug-metabolizing
enzymes as added variants
Include relevant age range: e.g., younger children and neonates
Design adequately powered studies
LC–MS liquid chromatography–mass spectrometry, PD pharmaco-
dynamic, PGx pharmacogenetic, PK pharmacokinetic
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